Transcatheter structural heart therapies stand to replace their open-heart counterparts thanks to technological innovations and expanded patient access.
Improved functionality across four valve sizes and lowest delivery profile on market, Evolut PRO+ TAVR System launches in U.S. as TAVR patient population grows.
Trials to examine efficacy of treatment with Pericardial TAVR System with the Everdur transcatheter heart valve and Coronatix Transfemoral Delivery Catheter.